Private equity giant Warburg Pincus is diving into specialty pharmaceuticals, launching Vertice Pharma and promising to invest up to $300 million in the company as it scouts for buyable assets.
Medtronic just announced the acquisition of Scotland's Aircraft Medical, a maker of video laryngoscopes to facilitate successful intubation of breathing tubes into the trachea, for $110 million in cash.
Depomed agreed to pay $25 million for the rights to a novel pain treatment from Germany's Grünenthal, signing a deal that will also settle the company's long-running patent lawsuit against Endo Pharmaceuticals
Dan Loeb, the activist investor who once called for Amgen to break itself in two, is now advising the Big Biotech to consider merging with Allergan, according to Bloomberg.
With pharma M&A growing at a steady clip, pressure from activist shareholders is also reaching new heights. But drugmakers have a few tricks up their sleeve for warding off the unwanted attention, including blacklisting firms to prevent them from taking a stake in the company once a deal goes through.
Laparoscopic surgery startup SurgiQuest has forced the hand of a potential acquirer. Last week, SurgiQuest filed to raise up to $75 million in an IPO. Now Conmed has said it will buy the Milford, CT, company instead for $265 million.
Merck announced Nov. 12 that it will acquire Harrisvaccines, a private Iowa company that made news in October when the USDA appointed it to manufacture avian influenza vaccines for an emergency stockpile.
Pharma's longest-running takeover battle of the year has come to an end--and not in pursuer Mylan's favor. The company has failed to garner the support necessary for a takeover of Perrigo, a target it's been pursuing since April. As of 8 a.m. Friday, about 40% of Perrigo's shares had been tendered, Mylan said, missing the 50% threshold necessary for it to push forward with the transaction.
BioDuro, once a division of PDD, has merged with contract manufacturer Formex, expanding its production capabilities in the U.S. while maintaining its research presence in China.
Veterinary diagnostics maker Heska's efforts to revamp its business model to get more revenue from recurring sources are paying off. Heska revealed Q3 revenues that beat the Street's expectations, partly fueled by a strong performance of its blood analyzer systems.